PharmaCyte Biotech (PMCB) Invested Capital (2016 - 2026)
PharmaCyte Biotech (PMCB) has disclosed Invested Capital for 16 consecutive years, with $38.1 million as the latest value for Q1 2026.
- Quarterly Invested Capital fell 5.31% to $38.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $38.1 million through Jan 2026, down 5.31% year-over-year, with the annual reading at $51.9 million for FY2025, 87.69% up from the prior year.
- Invested Capital for Q1 2026 was $38.1 million at PharmaCyte Biotech, up from $35.2 million in the prior quarter.
- The five-year high for Invested Capital was $91.3 million in Q1 2022, with the low at $27.6 million in Q2 2024.
- Average Invested Capital over 5 years is $54.9 million, with a median of $43.6 million recorded in 2025.
- The sharpest move saw Invested Capital skyrocketed 1410.68% in 2022, then tumbled 61.97% in 2024.
- Over 5 years, Invested Capital stood at $81.0 million in 2022, then tumbled by 54.63% to $36.8 million in 2023, then increased by 18.18% to $43.5 million in 2024, then fell by 18.91% to $35.2 million in 2025, then rose by 8.17% to $38.1 million in 2026.
- According to Business Quant data, Invested Capital over the past three periods came in at $38.1 million, $35.2 million, and $43.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.